| Dr Jean Claude Tabuteau, MD, MPH | |
|
345 S Congress Ave, Delray Beach, FL 33445-4617 | |
| (561) 274-3100 | |
| (561) 274-3144 |
| Full Name | Dr Jean Claude Tabuteau |
|---|---|
| Gender | Male |
| Speciality | General Practice |
| Experience | 48 Years |
| Location | 345 S Congress Ave, Delray Beach, Florida |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1619908704 | NPI | - | NPPES |
| 56161Z | Other | FL | MEDICARE PTAN |
| 0428906-00 | Medicaid | FL |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2083P0901X | Preventive Medicine - Public Health & General Preventive Medicine | ME47425 (Florida) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Florida Department Of Health | 3072424282 | 111 |
News Archive
Generex Biotechnology Corporation, the leader in drug delivery for metabolic diseases through the inner lining of the mouth, today announced that it is presenting study results at the 46th Annual Meeting of the European Association for the Study of Diabetes being held in Stockholm, Sweden, 20 - 24 September, 2010.
Lucideon, an international provider of materials development, testing and assurance, and Knight Mechanical Testing, an independent mechanical testing laboratory, are pleased to announce that they have entered into a Marketing and Commercial Collaboration Agreement. The agreement means that both partners will now be to offer a complete portfolio of testing and analysis services to the orthopaedic industry.
The study, published in CDC's Morbidity and Mortality Weekly Report (MMWR), highlights the efficacy of mRNA vaccines in protecting against SARS-CoV-2 infection.
Tokai Pharmaceuticals, Inc., a biopharmaceutical company focused on developing new treatments for prostate cancer, today announced the initiation of a Phase 1/2 clinical trial of its lead candidate TOK-001 for the treatment of patients with castration resistant prostate cancer (CRPC). TOK-001 is the only compound in development that combines three distinct mechanisms of action for the treatment of CRPC.
State regulators have approved premium increases averaging 2.3 percent for health insurance covering hundreds of thousands of residents, the most modest hikes in at least a decade and a sign that years of efforts to control costs may be working. The new rates are in Massachusetts' "small group'' market, which includes tens of thousands of small businesses as well as self-employed and formerly uninsured individuals.
› Verified 7 days ago
| Entity Name | Florida Department Of Health |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1134189103 PECOS PAC ID: 3072424282 Enrollment ID: O20040105000636 |
News Archive
Generex Biotechnology Corporation, the leader in drug delivery for metabolic diseases through the inner lining of the mouth, today announced that it is presenting study results at the 46th Annual Meeting of the European Association for the Study of Diabetes being held in Stockholm, Sweden, 20 - 24 September, 2010.
Lucideon, an international provider of materials development, testing and assurance, and Knight Mechanical Testing, an independent mechanical testing laboratory, are pleased to announce that they have entered into a Marketing and Commercial Collaboration Agreement. The agreement means that both partners will now be to offer a complete portfolio of testing and analysis services to the orthopaedic industry.
The study, published in CDC's Morbidity and Mortality Weekly Report (MMWR), highlights the efficacy of mRNA vaccines in protecting against SARS-CoV-2 infection.
Tokai Pharmaceuticals, Inc., a biopharmaceutical company focused on developing new treatments for prostate cancer, today announced the initiation of a Phase 1/2 clinical trial of its lead candidate TOK-001 for the treatment of patients with castration resistant prostate cancer (CRPC). TOK-001 is the only compound in development that combines three distinct mechanisms of action for the treatment of CRPC.
State regulators have approved premium increases averaging 2.3 percent for health insurance covering hundreds of thousands of residents, the most modest hikes in at least a decade and a sign that years of efforts to control costs may be working. The new rates are in Massachusetts' "small group'' market, which includes tens of thousands of small businesses as well as self-employed and formerly uninsured individuals.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Jean Claude Tabuteau, MD, MPH 7023 Lake Island Dr, Lake Worth, FL 33467-7950 Ph: (561) 967-4252 | Dr Jean Claude Tabuteau, MD, MPH 345 S Congress Ave, Delray Beach, FL 33445-4617 Ph: (561) 274-3100 |
News Archive
Generex Biotechnology Corporation, the leader in drug delivery for metabolic diseases through the inner lining of the mouth, today announced that it is presenting study results at the 46th Annual Meeting of the European Association for the Study of Diabetes being held in Stockholm, Sweden, 20 - 24 September, 2010.
Lucideon, an international provider of materials development, testing and assurance, and Knight Mechanical Testing, an independent mechanical testing laboratory, are pleased to announce that they have entered into a Marketing and Commercial Collaboration Agreement. The agreement means that both partners will now be to offer a complete portfolio of testing and analysis services to the orthopaedic industry.
The study, published in CDC's Morbidity and Mortality Weekly Report (MMWR), highlights the efficacy of mRNA vaccines in protecting against SARS-CoV-2 infection.
Tokai Pharmaceuticals, Inc., a biopharmaceutical company focused on developing new treatments for prostate cancer, today announced the initiation of a Phase 1/2 clinical trial of its lead candidate TOK-001 for the treatment of patients with castration resistant prostate cancer (CRPC). TOK-001 is the only compound in development that combines three distinct mechanisms of action for the treatment of CRPC.
State regulators have approved premium increases averaging 2.3 percent for health insurance covering hundreds of thousands of residents, the most modest hikes in at least a decade and a sign that years of efforts to control costs may be working. The new rates are in Massachusetts' "small group'' market, which includes tens of thousands of small businesses as well as self-employed and formerly uninsured individuals.
› Verified 7 days ago
Dr. Susan Etzi, M.D. Preventive Medicine Medicare: Not Enrolled in Medicare Practice Location: 7600 Lexington Club Blvd, Unit B, Delray Beach, FL 33446 Phone: 561-865-5104 | |
Dr. Bradley Stuart Hersh, M.D., M.P.H. Preventive Medicine Medicare: Not Enrolled in Medicare Practice Location: 16032 Lomond Hills Trl Apt 135, Delray Beach, FL 33446 Phone: 914-498-0723 Fax: 844-804-8331 | |
Lisa Salvati, MD Preventive Medicine Medicare: Not Enrolled in Medicare Practice Location: 13455 Military Trl, Suite A, Delray Beach, FL 33484 Phone: 561-495-4644 Fax: 561-495-5191 | |
Dr. Ethan Anglemyer, D.O. Preventive Medicine Medicare: Accepting Medicare Assignments Practice Location: 1440 N Federal Hwy Ste 18, Delray Beach, FL 33483 Phone: 305-791-2797 |